Your browser is no longer supported. Please, upgrade your browser.
Intec Pharma Ltd
Index- P/E- EPS (ttm)-4.08 Insider Own2.94% Shs Outstand4.50M Perf Week-10.09%
Market Cap17.24M Forward P/E- EPS next Y-2.45 Insider Trans0.00% Shs Float4.37M Perf Month-22.47%
Income- PEG- EPS next Q-0.87 Inst Own20.25% Short Float13.10% Perf Quarter-11.75%
Sales- P/S- EPS this Y173.30% Inst Trans- Short Ratio0.67 Perf Half Y-24.61%
Book/sh3.36 P/B1.14 EPS next Y-181.90% ROA- Target Price- Perf Year-15.86%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.20 - 15.82 Perf YTD11.01%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-75.78% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low74.09% ATR0.42
Employees36 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)40.76 Volatility6.93% 8.75%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.12 Prev Close3.96
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume856.97K Price3.83
Recom2.30 SMA20-10.31% SMA50-20.00% SMA200-23.64% Volume101,854 Change-3.28%
Dec-09-20Upgrade Ladenburg Thalmann Neutral → Buy $13
Oct-11-19Downgrade ROTH Capital Buy → Neutral $10 → $1
Mar-26-18Reiterated Maxim Group Buy $8 → $12
Feb-28-18Initiated Ladenburg Thalmann Buy
Feb-26-18Initiated H.C. Wainwright Buy
Sep-21-17Reiterated Oppenheimer Outperform $10 → $15
Sep-16-15Initiated Maxim Group Buy $9
Sep-11-15Initiated ROTH Capital Buy $9.50
Apr-14-21 03:16PM  
Apr-13-21 07:00PM  
Apr-07-21 06:16PM  
Apr-06-21 02:45PM  
Mar-31-21 02:06PM  
Mar-30-21 06:56PM  
Mar-26-21 11:02PM  
Mar-23-21 02:26PM  
Mar-22-21 08:16PM  
Mar-21-21 03:22AM  
Mar-20-21 12:52PM  
Mar-17-21 01:47PM  
Mar-16-21 08:18PM  
Mar-15-21 08:00AM  
Feb-10-21 04:17AM  
Dec-09-20 07:00AM  
Nov-05-20 07:00AM  
Oct-29-20 08:00AM  
Oct-08-20 07:00AM  
Sep-14-20 04:30PM  
Sep-08-20 07:00AM  
Aug-07-20 04:28PM  
Aug-05-20 07:00AM  
Jun-13-20 09:04AM  
Jun-05-20 12:00PM  
Jun-02-20 10:03AM  
May-28-20 08:00AM  
May-11-20 04:15PM  
May-04-20 03:33PM  
Mar-26-20 01:05PM  
Mar-13-20 07:30AM  
Feb-25-20 07:30AM  
Jan-30-20 10:44PM  
Jan-09-20 07:00AM  
Dec-23-19 07:51PM  
Dec-11-19 07:30AM  
Dec-06-19 07:30AM  
Dec-03-19 07:30AM  
Nov-13-19 07:00AM  
Nov-12-19 07:00AM  
Sep-25-19 07:00AM  
Sep-16-19 07:00AM  
Sep-03-19 07:00AM  
Aug-30-19 11:28AM  
Aug-13-19 10:09AM  
Aug-09-19 07:00AM  
Aug-06-19 12:00PM  
Jul-22-19 10:15AM  
Jul-03-19 05:00PM  
Jul-01-19 09:00AM  
Jun-28-19 05:45PM  
Jun-25-19 07:00AM  
Jun-19-19 07:00AM  
May-28-19 07:00AM  
May-20-19 07:00AM  
May-16-19 06:00AM  
May-07-19 07:00AM  
May-02-19 07:00AM  
Apr-30-19 07:00AM  
Apr-24-19 11:30AM  
Apr-01-19 07:00AM  
Mar-27-19 06:00AM  
Mar-13-19 07:00AM  
Feb-28-19 09:42AM  
Feb-27-19 07:00AM  
Feb-20-19 10:03AM  
Feb-19-19 07:00AM  
Jan-04-19 07:00AM  
Jan-02-19 07:00AM  
Dec-23-18 02:39AM  
Dec-19-18 09:28AM  
Dec-13-18 09:15AM  
Dec-11-18 10:37AM  
Dec-06-18 07:00AM  
Dec-03-18 06:50AM  
Nov-21-18 08:55AM  
Nov-09-18 07:00AM  
Nov-07-18 09:43AM  
Nov-06-18 07:00AM  
Nov-02-18 12:15PM  
Oct-22-18 07:00AM  
Sep-25-18 07:00AM  
Sep-20-18 07:00AM  
Aug-15-18 07:30AM  
Jul-20-18 06:00AM  
Jun-29-18 07:00AM  
May-31-18 08:30AM  
May-15-18 07:00AM  
Apr-26-18 07:40AM  
Apr-24-18 07:00AM  
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which has completed a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck Sharp & Dohme for the development of Accordion Pill; and a cannabinoid research collaboration agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was incorporated in 2000 and is based in Jerusalem, Israel.